SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Matthias Löhle, Carl-Johan Ramberg, Heinz Reichmann, Anthony H. V. Schapira, Early Versus Delayed Initiation of Pharmacotherapy in Parkinson’s Disease, Drugs, 2014, 74, 6, 645

    CrossRef

  2. 2
    David JM McGhee, Pamela L Royle, Paul A Thompson, David E Wright, John P Zajicek, Carl E Counsell, A systematic review of biomarkers for disease progression in Parkinson’s disease, BMC Neurology, 2013, 13, 1, 35

    CrossRef

  3. 3
    Catherine Cornu, Behrouz Kassai, Roland Fisch, Catherine Chiron, Corinne Alberti, Renzo Guerrini, Anna Rosati, Gerard Pons, Harm Tiddens, Sylvie Chabaud, Daan Caudri, Clément Ballot, Polina Kurbatova, Anne-Charlotte Castellan, Agathe Bajard, Patrice Nony, Experimental designs for small randomised clinical trials: an algorithm for choice, Orphanet Journal of Rare Diseases, 2013, 8, 1, 48

    CrossRef

  4. 4
    C.E. Clarke, How can we improve the design and endpoints of symptomatic and disease modifying clinical trials in Parkinson’s disease?, Basal Ganglia, 2012, 2, 4, 201

    CrossRef

  5. 5
    Alberto J Espay, Alfonso Fasano, Francesca Morgante, The six gaps in the search of neuroprotection for Parkinson’s disease, Expert Review of Neurotherapeutics, 2012, 12, 2, 111

    CrossRef

  6. 6
    Matthias Löhle, Heinz Reichmann, Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease, BMC Neurology, 2011, 11, 1, 112

    CrossRef

  7. 7
    Claire Henchcliffe, W. Lawrence Severt, Disease Modification in Parkinsonʼs Disease, Drugs & Aging, 2011, 28, 8, 605

    CrossRef

  8. 8
    C. Warren Olanow, Kathryn B. Wunderle, Karl Kieburtz, Milestones in movement disorders clinical trials: Advances and landmark studies, Movement Disorders, 2011, 26, 6
  9. 9
    Carl E. Clarke, Smitaa Patel, Natalie Ives, Caroline Rick, Keith Wheatley, Richard Gray, Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?, Movement Disorders, 2011, 26, 7
  10. 10
    Matthias Löhle, Heinz Reichmann, Clinical neuroprotection in Parkinson's disease — Still waiting for the breakthrough, Journal of the Neurological Sciences, 2010, 289, 1-2, 104

    CrossRef

  11. 11
    Sean R. Tunis, Joshua Benner, Mark McClellan, Comparative effectiveness research: Policy context, methods development and research infrastructure, Statistics in Medicine, 2010, 29, 19
  12. 12
    C. Warren Olanow, Karl Kieburtz, Defining disease-modifying therapies for PD—A road map for moving forward, Movement Disorders, 2010, 25, 12
  13. 13
    Shyamal H. Mehta, John C. Morgan, Kapil D. Sethi, Does Rasagiline Have a Disease-Modifying Effect on Parkinson’s Disease?, Current Neurology and Neuroscience Reports, 2010, 10, 6, 413

    CrossRef

  14. 14
    C. E. Clarke, Has drug therapy changed the natural history of Parkinson’s disease?, Journal of Neurology, 2010, 257, S2, 262

    CrossRef

  15. 15
    Mark F. Lew, Robert A. Hauser, Howard I. Hurtig, William G. Ondo, Joanne Wojcieszek, Tamar Goren, Cheryl J. Fitzer-Attas, Long-Term Efficacy of Rasagiline in Early Parkinson's Disease, International Journal of Neuroscience, 2010, 120, 6, 404

    CrossRef

  16. 16
    Raúl de la Fuente-Fernández, Michael Schulzer, Edwin Mak, Vesna Sossi, Trials of neuroprotective therapies for Parkinson’s disease: Problems and limitations, Parkinsonism & Related Disorders, 2010, 16, 6, 365

    CrossRef

  17. 17
    C. Warren Olanow, Olivier Rascol, Robert Hauser, Paul D. Feigin, Joseph Jankovic, Anthony Lang, William Langston, Eldad Melamed, Werner Poewe, Fabrizio Stocchi, Eduardo Tolosa, A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease, New England Journal of Medicine, 2009, 361, 13, 1268

    CrossRef

  18. 18
    Jose A. Obeso, Anthony H. Schapira, Compensatory mechanisms in Parkinson's disease, Movement Disorders, 2009, 24, 1
  19. 19
    C. Marin, E. Aguilar, G. Mengod, R. Cortés, J. A. Obeso, Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats, European Journal of Neuroscience, 2009, 30, 5
  20. 20
    Robert A. Hauser, Mark F. Lew, Howard I. Hurtig, William G. Ondo, Joanne Wojcieszek, Cheryl J. Fitzer-Attas, Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease, Movement Disorders, 2009, 24, 4
  21. 21
    Gwyn M. Vernon, Parkinson Disease and the Nurse Practitioner: Diagnostic and Management Challenges, The Journal for Nurse Practitioners, 2009, 5, 3, 195

    CrossRef

  22. 22
    Andrew J Lees, John Hardy, Tamas Revesz, Parkinson's disease, The Lancet, 2009, 373, 9680, 2055

    CrossRef

  23. 23
    Berend Arnold Ploeger, Nicholas H. G. Holford, Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis, Pharmaceutical Statistics, 2009, 8, 3
  24. 24
    Matthias Löhle, Alexander Storch, Orally disintegrating selegiline for the treatment of Parkinson's disease, Expert Opinion on Pharmacotherapy, 2008, 9, 16, 2881

    CrossRef

  25. 25
    C. Warren Olanow, Karl Kieburtz, Anthony H. V. Schapira, Why have we failed to achieve neuroprotection in Parkinson's disease?, Annals of Neurology, 2008, 64, S2